The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Most malignancies showed weak to moderate cytoplasmic positivity. Colorectal, thyroid, pancreatic, lung, gastric and endometrial cancers displayed strong staining in a few cases.
Cases of colorectal, hepatocellular and endometrial cancers showed strong cytoplasmic immunoreactivity. Malignant cells in general were moderately positive. Testicular, skin and urothelial cancers were weakly stained or negative in most cases while a majority malignant gliomas and lymphomas were negative.
Moderate cytoplasmic positivity was observed in most malignant cells. A few cases of malignant melanomas, colorectal, ovarian and liver cancers displayed strong positivity. Several cases of malignant gliomas and lymphomas, cervical and testis cancers were weakly stained or negative.
Validation
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
